Write in a clean editor, then format for NEJM Evidence in one click — DocuGuru applies the official Clinical & Medical Journals template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
NEJM Evidence is a peer-reviewed journal published by Clinical & Medical Journals, covering Health Systems, Economic Evaluations, Quality of Life, Statistical Methods in Clinical Trials, Diabetes Treatment and Management. Over its lifetime it has published 683 papers, which have received 13,760 citations.
| Publisher | Clinical & Medical Journals |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. NEJM Evidence. 2023;12(3):45–58.
Formats any DOI in NEJM Evidence style. No sign-up. |
| Publishes research in | Health Systems, Economic Evaluations, Quality of Life Statistical Methods in Clinical Trials Diabetes Treatment and Management Heart Failure Treatment and Management Meta-analysis and systematic reviews |
| ISSN | 2766-5526 |
| Citation impact (2-yr) | 5.74 |
| h-index | 55 |
| i10-index | 197 |
| Top institutions publishing here | Harvard University |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial of unresectable hepatocellular carcinoma. METHODS: In this global, open-label, phase 3 trial, the majority of…
BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer. METHODS: In this double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with previously…
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are not yet used in the risk stratification of patients with MDS. METHODS: To develop a clinical-molecular prognostic model (IPSS-Molecular [IPSS-M]), pretreatment diagnostic or peridiagnostic samples…
BACKGROUND: Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation hormonal agent abiraterone to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and…
Background: Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) are defined by somatic mutations in genes associated with myeloid neoplasms (MN) at a variant allele fraction (VAF) ≥ 0.02, in the absence and presence of cytopenia, respectively. CHIP/CCUS is highly prevalent in adults and defining predictors of MN risk would…
